Medicare AdvantagePrior AuthMedium impact
Topical Antifungals (Revised)
Humana·Dermatology, Internal Medicine, Family Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2020
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its Topical Antifungals pharmacy coverage policy, implementing a step therapy requirement effective January 1, 2020 (with policy revision dated July 23, 2025). Members must have documented previous treatment failure, contraindication, or intolerance to at least two first-line topical antifungals (clotrimazole cream, ciclopirox, or ketoconazole cream) within the past 12 months before coverage is approved for branded agents like Exelderm, Luzu, Naftin, or sulconazole products.
Action Required
Before processing claims for topical antifungal medications (Exelderm, Luzu, Naftin, luliconazole, naftifine, sulconazole): (1) Billing team must verify prior authorization requirements in the system for all topical antifungal medications covered under Humana Medicare Advantage plans. (2) Update claim submission workflows to flag these medications for step therapy review before adjudication. (3) Providers must document in patient records evidence that the member has had prior treatment failure, contraindication, or intolerance to TWO of the following within the past 12 months: clotrimazole cream, ciclopirox 0.77% cream/gel/suspension, or ketoconazole cream. (4) Front desk and prior authorization staff must include this documentation requirement on authorization request forms. (5) Update billing software rules to deny or pend claims for these topical antifungals without documented step therapy compliance. Claims submitted without evidence of prior first-line therapy failure will be denied and require resubmission with proper documentation.